Page 58 - Medication Guide News Today

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohns...

(BPT) - Spring has sprung, and for many of us, that means the start of bothersome allergy symptoms. In fact, between 30 and 60 million Americans are affected by environmental allergies each year, [1] making it one of the leading causes of chronic disease in the U.S. Allergies are caused by the body’s immune system overreacting to substances in the environment, causing symptoms like a runny nose, sneezing, congestion or sinus pressure. One of the more common environmental allergy triggers i...

Published: May 20, 2021 in the first quarter of 2021 for: VLA15, currently the only clinical stage vaccine candidate against Lyme disease Initiation of additional Phase 2 trial to accelerate pediatric development VLA2001, currently the only inactivated, adjuvanted vaccine candidate for COVID-19 in clinical trials in Europe: Initiation of pivotal Phase 3 clinical trial Participation in the world’s first COVID-19 vaccine booster trial in the UK Publication of Phase 1/2 results VLA1553, curr...

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it and its investigator sponsors will present four new abstracts at the virtual...

AbbVie to Showcase Breadth of Oncology Portfolio and Pipeline at the 2021 ASCO and EHA Annual Congresses ABBVie will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical Oncology Annual Meeting and the virtual European Hematology Association congress . “We are advancing discovery and innovation to improve on the standards of care for blood cancer treatment,” said Mohamed Zaki M.D., Ph.D., vice president and global head of onco...

MorphoSys AG: MorphoSys to Present Data on Tafasitamab (Monjuvi) at the 2021 ASCO Annual Meeting PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 19, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new data from the tafasitamab (Monjuvi (R)) development program will be presented at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, 2021. Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, which was approved as M...

AstraZeneca : ASCO 2021 Data Support Ambition to Revolutionize Cancer Outcomes by Treating Earlier and Transforming the Patient Experience 05/19/2021 | 05:06pm EDT Send by mail : Message : Required fields LYNPARZA is the first targeted medicine to show clinical benefit in the adjuvant setting for patients with germline BRCA-mutated high-risk HER2-negative early breast cancer CALQUENCE shows sustained four-year clinical benefit in 1st-line chronic lymphocytic leukemia and lower atrial fibrillat...

Share this article Share this article RARITAN, N.J., May 16, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO ® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it w...

In Pivotal Study, KEYTRUDA ® In Combination With Chemotherapy Before Surgery and Continuing as a Single Agent After Surgery Showed Statistically Significant Improvement in EFS Versus Pre-Operative Chemotherapy KEYTRUDA Is the First Anti-PD-1 Therapy to Show a Statistically Significant Improvement in EFS as Neoadjuvant and Adjuvant Therapy for TNBC Merck known as MSD outside the United States and Canada, today … In Pivotal Study, KEYTRUDA ® (pembrolizumab) In Combination With Chemotherap...

Bristol Myers Squibb Presents New Research at ASCO and EHA 2021 Featuring Novel Approaches and Demonstrating Significant Progress to Improve Survival in Cancer and Blood Disorders First Phase 3 data from the RELATIVITY-047 trial highlight clinical benefit of LAG-3 blocking antibody relatlimab the company’s third distinct checkpoint inhibitor in combination with nivolumab for patients with previously untreated unresectable or metastatic melanoma First disclosure of results from CheckMate -648 ...